News
Aruvant to Participate in SVB Leerink’s Biopharma Private Company Connect December 15 to 17
NEW YORK and BASEL, Switzerland, Dec. 1, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment
Aruvant Receives Orphan Designation from European Medicines Agency for Gene Therapy ARU-1801 for Sickle Cell Disease
NEW YORK and BASEL, Switzerland, Nov. 16, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment
Aruvant Announces Updated Data to be Presented in Oral Presentation of ARU-1801 Data at the 62nd American Society of Hematology (ASH) Annual Meeting
–Ongoing manufacturing improvements shows enhanced efficacy of ARU-1801 for the treatment of sickle cell disease– New York, NY, Nov. 4, 2020 –Aruvant Sciences, a private
Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy
Hanover, MD, and New York, NY, October 12, 2020 – The Sickle Cell Disease Association of America (SCDAA) and Aruvant Sciences are proud to announce
Aruvant to Present at Investor and Scientific Conferences in October
NEW YORK and BASEL, Switzerland, Sept. 29, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment
Aruvant Appoints Dr. Palaniappan as Chief Technology Officer
Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than
Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer
Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell
Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a
Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a